Suppr超能文献

细胞因子和趋化因子在非酒精性脂肪性肝病中的作用。

Role of cytokines and chemokines in non-alcoholic fatty liver disease.

机构信息

Division of Cardiology, Foundation for Medical Researches, Faculty of Medicine, Geneva University Hospital, 1211 Geneva, Switzerland.

出版信息

World J Gastroenterol. 2012 Feb 28;18(8):727-35. doi: 10.3748/wjg.v18.i8.727.

Abstract

Non-alcoholic fatty liver disease (NAFLD) includes a variety of histological conditions (ranging from liver steatosis and steatohepatitis, to fibrosis and hepatocarcinoma) that are characterized by an increased fat content within the liver. The accumulation/deposition of fat within the liver is essential for diagnosis of NAFLD and might be associated with alterations in the hepatic and systemic inflammatory state. Although it is still unclear if each histological entity represents a different disease or rather steps of the same disease, inflammatory processes in NAFLD might influence its pathophysiology and prognosis. In particular, non-alcoholic steatohepatitis (the most inflamed condition in NAFLDs, which more frequently evolves towards chronic and serious liver diseases) is characterized by a marked activation of inflammatory cells and the upregulation of several soluble inflammatory mediators. Among several mediators, cytokines and chemokines might play a pivotal active role in NAFLD and are considered as potential therapeutic targets. In this review, we will update evidence from both basic research and clinical studies on the potential role of cytokines and chemokines in the pathophysiology of NAFLD.

摘要

非酒精性脂肪性肝病 (NAFLD) 包括多种组织学病变(从肝脂肪变性和脂肪性肝炎,到纤维化和肝癌),其特征是肝脏内脂肪含量增加。肝内脂肪的蓄积/沉积是诊断 NAFLD 的必要条件,并且可能与肝和全身炎症状态的改变有关。尽管尚不清楚每种组织学病变是否代表不同的疾病,还是同一种疾病的不同阶段,但 NAFLD 中的炎症过程可能会影响其病理生理学和预后。特别是,非酒精性脂肪性肝炎(NAFLD 中最具炎症性的病变,更常发展为慢性和严重的肝病)的特征是炎症细胞的显著激活和几种可溶性炎症介质的上调。在几种介质中,细胞因子和趋化因子可能在 NAFLD 中发挥关键作用,并被认为是潜在的治疗靶点。在这篇综述中,我们将更新基础研究和临床研究中关于细胞因子和趋化因子在 NAFLD 病理生理学中潜在作用的证据。

相似文献

1
Role of cytokines and chemokines in non-alcoholic fatty liver disease.
World J Gastroenterol. 2012 Feb 28;18(8):727-35. doi: 10.3748/wjg.v18.i8.727.
2
The role of cytokines and chemokines in the development of steatohepatitis.
Semin Liver Dis. 2007 May;27(2):173-93. doi: 10.1055/s-2007-979470.
3
An Update on the Chemokine System in the Development of NAFLD.
Medicina (Kaunas). 2022 Jun 5;58(6):761. doi: 10.3390/medicina58060761.
4
Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis.
World J Gastroenterol. 2016 Nov 7;22(41):9096-9103. doi: 10.3748/wjg.v22.i41.9096.
5
Chemokines and Chemokine Receptors in the Development of NAFLD.
Adv Exp Med Biol. 2018;1061:45-53. doi: 10.1007/978-981-10-8684-7_4.
6
Inflammatory mediators of hepatic steatosis.
Mediators Inflamm. 2010;2010:837419. doi: 10.1155/2010/837419. Epub 2010 Mar 16.
7
The role of hepassocin in the development of non-alcoholic fatty liver disease.
J Hepatol. 2013 Nov;59(5):1065-72. doi: 10.1016/j.jhep.2013.06.004. Epub 2013 Jun 18.
8
Apoptosis and cytokines in non-alcoholic steatohepatitis.
Clin Liver Dis. 2009 Nov;13(4):565-80. doi: 10.1016/j.cld.2009.07.003.
9
Expression of inflammation-related genes is altered in gastric tissue of patients with advanced stages of NAFLD.
Mediators Inflamm. 2013;2013:684237. doi: 10.1155/2013/684237. Epub 2013 Mar 30.

引用本文的文献

1
3
Sexual dimorphism of MASLD-driven bone loss.
Sci Rep. 2025 Jul 2;15(1):23090. doi: 10.1038/s41598-025-08693-w.
5
Sexual dimorphism of MASLD-driven bone loss.
bioRxiv. 2024 Nov 28:2024.11.25.625246. doi: 10.1101/2024.11.25.625246.
6
Editorial: Inflammatory responses on the road from NASH to HCC: pathogenic mechanisms and possible therapeutic strategies.
Front Immunol. 2024 Nov 1;15:1512363. doi: 10.3389/fimmu.2024.1512363. eCollection 2024.
7
Metabolic regulation of the immune system in health and diseases: mechanisms and interventions.
Signal Transduct Target Ther. 2024 Oct 9;9(1):268. doi: 10.1038/s41392-024-01954-6.
10
Impact of Lipids on Insulin Resistance: Insights from Human and Animal Studies.
Drug Des Devel Ther. 2024 Jul 31;18:3337-3360. doi: 10.2147/DDDT.S468147. eCollection 2024.

本文引用的文献

1
CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice.
Eur Heart J. 2012 Aug;33(15):1964-74. doi: 10.1093/eurheartj/ehr127. Epub 2011 May 23.
3
Relationship between nonalcoholic fatty liver disease and metabolic syndrome.
J Dig Dis. 2011 Apr;12(2):125-30. doi: 10.1111/j.1751-2980.2011.00487.x.
5
Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation.
Curr Pharm Des. 2011;17(1):1-8. doi: 10.2174/138161211795049796.
7
Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice.
J Clin Invest. 2010 Nov;120(11):4129-40. doi: 10.1172/JCI41732. Epub 2010 Oct 18.
8
Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance.
World J Gastroenterol. 2010 Oct 14;16(38):4773-83. doi: 10.3748/wjg.v16.i38.4773.
9
Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome.
Clin Chim Acta. 2011 Jan 14;412(1-2):143-7. doi: 10.1016/j.cca.2010.09.025. Epub 2010 Sep 29.
10
TGF-ß in wound healing: a review.
J Wound Care. 2010 Sep;19(9):403-6. doi: 10.12968/jowc.2010.19.9.78235.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验